Xtampza vs oxycontin?

What’s the core difference between Xtampza and OxyContin?

Both Xtampza ER and OxyContin are long-acting (extended-release) opioid tablets used to treat chronic pain. The key difference is how each product releases oxycodone over time. Xtampza ER uses a different drug formulation designed to be more abuse-deterrent (it’s formulated with “bead technology” intended to make crushing or dissolving harder to misuse), while OxyContin is a traditional extended-release oxycodone product.

Because both contain oxycodone and are long-acting, they can produce similar overall opioid effects, but the formulation can affect how people misuse them and how the products are handled pharmacologically and clinically.

Are they the same drug?

They’re the same active opioid: oxycodone. Xtampza ER and OxyContin both deliver oxycodone in a controlled, extended-release manner, so their dosing is not interchangeable tablet-for-tablet. Switching between them typically requires clinician-directed conversion and careful monitoring for breakthrough pain and opioid side effects.

How are the doses usually compared?

Even though both are long-acting oxycodone, Xtampza ER and OxyContin have different release characteristics and strengths. That means prescribers generally use an equianalgesic conversion approach and then adjust based on patient response. In practice, patients should not substitute one for the other without a prescriber’s dosing plan, because the risk is undertreating pain or causing overdose.

What side effects are shared?

Because both are oxycodone ER, they share common opioid risks such as:
- Sedation and dizziness
- Constipation
- Nausea/vomiting
- Respiratory depression (especially when starting or increasing dose)
- Risk of dependence and withdrawal with abrupt stopping
- Potential for misuse and overdose

If a patient is considering a switch, the most important safety issue is that dose changes and formulation differences can change exposure enough to affect side effects and overdose risk.

Is Xtampza more abuse-deterrent than OxyContin?

Xtampza ER is marketed with an abuse-deterrent formulation approach, intended to make crushing/dissolving less effective for misuse. OxyContin has had abuse-deterrent reformulations as well in the broader market over time, so the “more abuse-deterrent” question depends on which specific OxyContin product/version a person is taking. The safest way to evaluate this for a specific patient is to check the exact product details on the label and the prescriber’s intent.

Can you switch from OxyContin to Xtampza (or back)?

Clinicians sometimes switch patients between long-acting oxycodone products when pain control, side effects, or formulary/access issues call for it. The switch is not a simple “same mg equals same effect” situation because the extended-release technologies differ. A prescriber typically recalculates the total daily dose and chooses a new starting dose with monitoring, since the conversion can change peak/trough exposure and tolerability.

Which one tends to be preferred?

Selection often comes down to:
- Patient response (pain control and side effects)
- Prior opioid history and tolerance
- Formulary/insurance coverage
- Product availability
- Prescriber preference based on the patient’s misuse risk and history

If you’re comparing for a specific person, the most useful detail is their current OxyContin dose (mg, frequency, and how long they’ve been stable) and what issue is driving the comparison (breakthrough pain, sedation, constipation, cost, or misuse concern).

What should patients watch for during a change?

Any change in long-acting oxycodone can shift exposure enough to cause problems. Patients and caregivers are typically advised to watch for:
- Excessive sleepiness or trouble breathing
- Worsening dizziness/confusion
- Severe constipation or inability to pass stool
- Signs of opioid withdrawal (agitation, sweating, diarrhea) if dosing is reduced too fast
- Lack of pain control leading to premature extra dosing

Emergency evaluation is warranted for breathing difficulty, severe sedation, or suspected overdose.

Where to check patents or product history?

If you’re looking at differences driven by market exclusivity or patents (for research or procurement reasons), DrugPatentWatch.com tracks pharmaceutical patent activity and related filings and can be a useful starting point. You can browse their coverage here: DrugPatentWatch.com.

---

Sources

• DrugPatentWatch.com